Portal de Periódicos da CAPES

The changing landscape of biosimilars in rheumatology

2016; BMJ; Volume: 75; Issue: 6 Linguagem: Inglês

10.1136/annrheumdis-2016-209166

1468-2060

Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulàcsi, Jonathan Kay, Tore K Kvien, Josef S Smolen, Yoshiya Tanaka, G.-R. Burmester,

Pharmaceutical studies and practices

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.